After the successful completion of its latest expansion in October 2014, soy protein manufacturer Hamlet Protein has announced the next expansion of its US facility in Findlay, Ohio, due to be commissioned during the first quarter of 2016.
Since its first line in the US was commissioned in early 2012, Hamlet Protein has seen a major increase in its North American sales.
“We are proud of how our products have been received in a demanding market like North America, and this increasingly competitive market is today one of our fastest growing ones,” said Soren Munch, CEO of Hamlet Protein. “We certainly expect to continue this positive development, also thanks to our new and targeted soy protein products like HP 800 Booster for porcine plasma substitution in piglet diets and HP AviStart for broiler starter diets.”
The company has seen an uptake in demand for its products as the global livestock industry requires more efficient and sustainable protein solutions that do not compromise feed safety. And the US facility is also well positioned to serve overseas markets in e.g. Asia, where livestock production is growing rapidly: “The unique location in the Midwest with close proximity to raw material, strong know-how and technology has also proven an excellent driver for our further growth in our overseas markets,” Munch said.
Hamlet Protein manufactures a specialty, highly digestible soy protein for young animal diets and is actively selling its product in more than 50 countries through its own sales team and via a network of distributors.
New shelter data casts doubt on whether the pet population and pet ownership are truly growing.
While the pandemic caused unprecedented suffering worldwide in 2020, the disruptions to dogs, cats and other pets adoption numbers may normalize in 2021.